Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs

Prostate

Volumn 73, Issue 15, 2013, Pages 1651-1659

  Jiang, Haowen ^a   Liu, Fang ^a,b   Wang, Zhong ^c   Na, Rong ^a,b,c   Zhang, Limin ^a   Wu, Yishuo ^a   Zheng, Jie ^a   Lin, Xiaoling ^a,b   Jiang, Deke ^b   Sun, Jielin ^c   Zheng, S Lilly ^c   Ding, Qiang ^a   Xu, Jianfeng ^a,b,c  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ChinaPCa; PSA; risk assessment; SNPs

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CHINESE; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

CHINAPCA; PSA; RISK ASSESSMENT; SNPS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CHINA; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84884910670     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22661     Document Type: Article

References (21)

1. Hsing AW, Tsao L, Devesa SS,. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85 (1): 60-67.
2. Ye DW, Li CL, Zhou FJ, Yao XD, Zhang SL, Dai B, Zhang HL, Zhu Y, Shen YJ,. Epidemiological trends of prostate cancer: Retrospect and prospect. China Oncology 2007; 17: 4.
3. Na R, Jiang H, Kim S-T, Wu Y, Tong S, Zhang L, Xu J, Sun Y, Ding Q,. Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011. PLoS ONE 2012; 7 (11): e49914.
4. Moyer VA,. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157 (2): 120-134.
5. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, Mangold LA, Mohr P, Bartsch G, Klocker H, Horninger W, Partin AW,. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: Preliminary analysis. Urology 2003; 61: 274-276.
6. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB,. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59 (23): 5975-5979.
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
8. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Gronberg H,. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358 (9): 910-919.
9. Xu J, Sun J, Kader AK, Lindstrom S, Wiklund F, Hsu FC, Johansson JE, Zheng SL, Thomas G, Hayes RB, Kraft P, Hunter DJ, Chanock SJ, Isaacs WB, Gronberg H,. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009; 69 (14): 1565-1572.
10. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA,. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185 (5): 1650-1655.
11. Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J,. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010; 184 (5): 1947-1952.
12. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG,. Combining urinary detection of TMPRS S2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2013; 31 (5): 566-571.
13. Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D'Amato M, Adolfsson J, Gronberg H,. Polygenic risk score improves prostate cancer risk prediction: Results from the Stockholm-1 cohort study. Eur Urol 2011; 60 (1): 21-28.
14. Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J,. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: Findings from the REDUCE Trial. Eur Urol 2012; 62 (6): 953-961.
15. Na R, Liu F, Zhang P, Ye D, Xu C, Shao Q, Qi J, Wang X, Chen Z, Wang M, He D, Wang Z, Zhou F, Yuan J, Gao X, Wei Q, Yang J, Jiao Y, Ou-Yang J, Zhu Y, Wu Q, Chen H, Lu D, Shi R, Lin X, Jiang H, Wang Z, Jiang D, Sun J, Zheng S, Ding Q, Mo Z, Sun Y, Xu J,. Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate 2012; (in press).
16. Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, Wang Z, Chen H, Gao X, Wang G, Chu LW, Ding Q, OuYang J, Gao X, Huang Y, Chen Y, Gao YT, Zhang ZF, Rao J, Shi R, Wu Q, Wang M, Zhang Z, Zhang Y, Jiang H, Zheng J, Hu Y, Guo L, Lin X, Tao S, Jin G, Sun J, Lu D, Zheng SL, Sun Y, Mo Z, Xu J,. Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci 2011; 102 (10): 1916-1920.
17. Wang M, Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, Wang Z, Chen H, Gao X, Wang G, Chu LW, Ding Q, OuYang J, Gao X, Huang Y, Chen Y, Gao YT, Zhang ZF, Rao J, Shi R, Wu Q, Zhang Y, Jiang H, Zheng J, Hu Y, Guo L, Lin X, Tao S, Jin G, Sun J, Lu D, Zheng SL, Sun Y, Mo Z, Yin C, Zhang Z, Xu J,. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: A case-control study in the ChinaPCa consortium. Carcinogenesis 2012; 33 (2): 356-360.
18. Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, Wang X, Qi J, Chen Z, Zhou F, Wang M, Wang Z, He D, Wu D, Gao X, Yuan J, Wang G, Xu Y, Wang G, Dong P, Jiao Y, Yang J, Ou-Yang J, Jiang H, Zhu Y, Ren S, Zhang Z, Yin C, Wu Q, Zheng Y, Turner AR, Tao S, Na R, Ding Q, Lu D, Shi R, Sun J, Liu F, Zheng SL, Mo Z, Sun Y, Xu J,. A novel Germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 2013; 73 (2): 169-175.
19. Xu J, Mo Z, Ye D, Wang M, Liu F, Jin G, Xu C, Wang X, Shao Q, Chen Z, Tao Z, Qi J, Zhou F, Wang Z, Fu Y, He D, Wei Q, Guo J, Wu D, Gao X, Yuan J, Wang G, Xu Y, Wang G, Yao H, Dong P, Jiao Y, Shen M, Yang J, Ou-Yang J, Jiang H, Zhu Y, Ren S, Zhang Z, Yin C, Gao X, Dai B, Hu Z, Yang Y, Wu Q, Chen H, Peng P, Zheng Y, Zheng X, Xiang Y, Long J, Gong J, Na R, Lin X, Yu H, Wang Z, Tao S, Feng J, Sun J, Liu W, Hsing A, Rao J, Ding Q, Wiklund F, Gronberg H, Shu XO, Zheng W, Shen H, Jin L, Shi R, Lu D, Zhang X, Sun J, Zheng SL, Sun Y,. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet 2012; 44: 1231-1235.
20. Zheng J, Liu F, Lin X, Wang X, Ding Q, Jiang H, Chen H, Lu D, Jin G, Hsing AW, Shao Q, Qi J, Ye Y, Wang Z, Gao X, Wang G, Chu LW, Ouyang J, Huang Y, Chen Y, Gao Y, Shi R, Wu Q, Wang M, Zhang Z, Hu Y, Sun J, Zheng SL, Gao X, Xu C, Mo Z, Sun Y, Xu J,. Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs. Prostate 2012; 72 (5): 577-583.
21. Macinnis RJ, Antoniou AC, Eeles RA, Severi G, Al Olama AA, McGuffog L, Kote-Jarai Z, Guy M, O'Brien LT, Hall AL, Wilkinson RA, Sawyer E, Ardern-Jones AT, Dearnaley DP, Horwich A, Khoo VS, Parker CC, Huddart RA, Van As N, McCredie MR, English DR, Giles GG, Hopper JL, Easton DF,. A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact. Genet Epidemiol 2011; 35 (6): 549-556.